Publications

June 8, 2021

COM701 with or without nivolumab: Results of an ongoing phase 1 study of safety, tolerability and preliminary antitumor activity in patients with advanced solid malignancies (NCT03667716)

Daniel A. Vaena, et al, ASCO Annual Meeting

April 13, 2021

Therapeutic Targeting of Checkpoint Receptors within the DNAM-1 Axis

Zoya Alteber, Maya F Kotturi, Sarah Whelan, et al.

November 5, 2020

PVRIG is a novel NK cell immune checkpoint receptor in acute myeloid leukemia

Jessica Li, et al, Haematologica

October 27, 2020

Rationalizing Combination Strategies to Maximize Clinical Response as Novel ICI Therapies Emerge

Eran Ophir, TIGIT Therapies Digital Summit

April 27, 2020

COM701 Demonstrates Antitumor Activity as Monotherapy and in Combination with Nivolumab in Patients with Advanced Malignancies

Ryan Sullivan, et al, AACR Annual Meeting

April 20, 2020

Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2)

Julia Huetter, et al, Cancer Immunology Research

February 6, 2020

A Phase 1 Study Evaluating COM701 Monotherapy and in Combination with Nivolumab in Patients with Advanced Solid Malignancies

RJ Sullivan, et al, ASCO-SITC Clinical Immuno-Oncology Symposium

December 10, 2019

Activation of Human NK Cells Modulates Expression of the Inhibitory Reception PVRIG

Jessica Li, el al, The Australian and New Zealand Society for Immunology (ASI) Annual Meeting

November 9, 2019

Phase 1 Study of COM701 Monotherapy and in Combination with Nivolumab in Patients with Advanced Solid Tumors

E. Ileana Dumbrava, et al, SITC Annual Meeting

COM902, a Novel Therapeutic Antibody Targeting TIGIT Augments T Cell Function and the Activity of PVRIG Pathway Blockade In Vitro and In Vivo

Kathryn Logronio, et al, SITC Annual Meeting